Table 1.
Cohort characteristics by planned endocrine therapy at baseline.
| Characteristics N (% or as described below) |
All patients 15 815 |
Non-users 3668 |
Tamoxifen only 6235 |
AI only 1481 |
AI/tamoxifen 4431 |
p-value |
|---|---|---|---|---|---|---|
|
Age at diagnosis Median (min-max) ≤60 61–65 66–70 71–75 >75 |
66 (34–101) 3944 (24.9) 3529 (22.3) 2997 (19.0) 2074 (13.1) 3271 (20.7) |
65 (34–97) 1001 (27.3) 849 (23.1) 684 (18.6) 457 (12.5) 677 (18.5) |
66 (34–97) 1584 (25.4) 1416 (22.7) 1163 (18.7) 799 (12.8) 1273 (20.4) |
69 (38–101) 245 (16.5) 274 (18.5) 269 (18.2) 194 (13.1) 499 (33.7) |
66 (38–97) 1114 (25.1) 990 (22.3) 881 (19.9) 624 (14.1) 822 (18.6) |
<0.001 |
| Follow up Median (min-max) |
46.8 (6–97) |
46.8 (6–97) |
55.0 (6–97) |
49.7 (6–97) |
37.7 (6–97) |
<0.001 |
| Marital status | ||||||
| Married | 8057 (50.9) | 1925 (52,4) | 3133 (50.2) | 709 (47.8) | 2290 (51.6) | |
| Not married | 1825 (11.5) | 410 (11.2) | 730 (11.7) | 146 (9.9) | 539 (12.2) | <0.001 |
| Divorced | 3093 (19.6) | 685 (18.7) | 1245 (20.0) | 233 (15.7) | 930 (21.0) | |
| Widowed Missing |
2828 (17.9) 12 (0.1) |
646 (17.6) 2 (0.1) |
1123 (18.0) 4 (0.1) |
392 (26.5) 1 (0.1) |
667 (15.1) 5 (0.1) |
|
| Family income (quartile) | ||||||
| 1 (lowest) | 3924 (24.8) | 948 (25.8) | 1521 (24.4) | 508 (34.3) | 947 (21.4) | |
| 2 | 3947 (25.0) | 903 (24.6) | 1609 (25.8) | 394 (26.6) | 1041 (23.5) | <0.001 |
| 3 | 3952 (25.0) | 895 (24.4) | 1540 (24.7) | 342 (23.1) | 1175 (26.5) | |
| 4 (highest) | 3950 (25.0) | 916 (25.0) | 1550 (24.9) | 231 (15.6) | 1253 (28.3) | |
| Missing |
42 (0.3) |
6 (0.2) |
15 (0.2) |
6 (0.4) |
15 (0.3) |
|
| Charlson Comorbidity Index | ||||||
| 0 | 12953 (81.9) | 2996 (81.7) | 5222 (83.8) | 1092 (73.7) | 3643 (82.2) | |
| 1 | 1494 (9.4) | 363 (9.9) | 529 (8.5) | 193 (13.0) | 409 (9.2) | <0.001 |
| 2 | 901 (5.7) | 201 (5.5) | 332 (5.3) | 111 (7.5) | 257 (5.8) | |
| 3+ |
467 (3.0) |
108 (2.9) |
152 (2.4) |
85 (5.7) |
122 (2.8) |
|
| Breast cancer side | ||||||
| Left | 8220 (52.0) | 1925 (52.5) | 3227 (51.8) | 779 (52.6) | 2289 (51.7) | 0.824 |
| Right |
7595 (48.0) |
1743 (47.5) |
3008 (48.2) |
702 (47.4) |
2142 (48.3) |
|
| Stage of breast cancer | ||||||
| Stage I | 7582 (47.9) | 1896 (51.7) | 4102 (65.8) | 304 (20.5) | 1280 (28.9) | |
| Stage II | 5741 (36.3) | 1038 (28.3) | 1633 (26.2) | 648 (43.8) | 2422 (54.7) | <0.001 |
| Stage III | 1738 (11.0) | 433 (11.8) | 247 (4.0) | 432 (29.2) | 626 (14.1) | |
| Missing |
754 (4.8) |
301 (8.2) |
253 (4.1) |
97 (6.5) |
103 (2.3) |
|
| Estrogen receptor status | ||||||
| Positive | 13477 (85.2) | 1498 (40.8) | 6179 (99.1) | 1444 (97.5) | 4356 (98.3) | |
| Negative | 2083 (13.2) | 1995 (54.4) | 29 (0.5) | 19 (1.3) | 40 (0.9) | <0.001 |
| Missing |
255 (1.6) |
175 (4.8) |
27 (0.4) |
18 (1.2) |
35 (0.8) |
|
|
HER2-status Positive Negative Missing |
1628 (10.3) 12029 (76.1) 2158 (13.6) |
679 (18.5) 2448 (66.7) 541 (14.7) |
230 (3.7) 4683 (75.1) 1322 (21.2) |
222 (15.0) 1170 (79.0) 89 (6.0) |
497 (11.2) 3728 (84.1) 206 (4.6) |
<0.001 |
| Type of surgery | ||||||
| Mastectomy | 6442 (40.7) | 1525 (41.6) | 1937 (31.1) | 909 (61.4) | 2071 (46.7) | <0.001 |
| Breast conserving |
9373 (59.3) |
2143 (58.4) |
4298 (68.9) |
572 (38.6) |
2360 (53.3) |
|
| Postoperative chemotherapy | ||||||
| No | 11031 (69.8) | 2222 (60.6) | 5445 (87.3) | 696 (65.4) | 2395 (54.1) | |
| Anthracycline-taxane based | 2635 (16.7) | 836 (22.8) | 447 (7.2) | 318 (21.5) | 1034 (23.3) | <0.001 |
| Only anthracycline-based | 1186 (7.5) | 357 (9.7) | 195 (3.1) | 107 (7.2) | 527 (11.9) | |
| Only taxane-based | 651 (4.1) | 172 (4.7) | 84 (1.3) | 81 (5.5) | 314 (7.1) | |
| Other | 312 (2.0) | 81 (2.2) | 64 (1.0) | 6 (0.4) | 161 (3.6) | |
|
Trastuzumab |
1182 (7.5) |
500 (13.6) |
124 (2.0) |
141 (9.5) |
417 (9.4) |
<0.001 |
|
Radiotherapy |
11115 (70.3) |
2516 (68.6) |
4348 (69.7) |
879 (59.4) |
3372 (76.1) |
<0.001 |
| Cardiovascular medication at diagnosis | ||||||
| Antidiabetics | 1242 (7.9) | 273 (7.4) | 467 (7.5) | 168 (11.3) | 334 (7.5) | <0.001 |
| Antitrombotics | 3076 (19.4) | 716 (19.5) | 1152 (18.5) | 393 (26.5) | 815 (18.4) | <0.001 |
| Lipid modifiers | 3926 (24.8) | 951 (25.9) | 1457 (23.4) | 418 (28.2) | 1100 (24.8) | <0.001 |
| Cardiac therapy | 1668 (10.5) | 383 (10.4) | 652 (10.5) | 230 (15.5) | 403 (9.1) | <0.001 |
| Antihypertensives | 9520 (60.2) | 2132 (58.1) | 3715 (59.6) | 1020 (68.9) | 2653 (59.9) | <0.001 |